News

Researchers in Iran are conducting a clinical trial to test the effects of taking ginger supplements for people with relapsing-remitting multiple sclerosis (RRMS). Ginger extracts have shown some promise in animal models of multiple sclerosis (MS), but no trial has yet determined the impact that ginger supplements may…

A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access program is continuing to show improvements 11 months after starting the therapy, according to an update from foralumab’s developer, Tiziana Life Sciences. The patient, dubbed EA2, experienced a…

The risk of developing multiple sclerosis (MS) doesn’t seem to be influenced by consuming alcohol, according to a large-scale analysis in the U.K. After adjusting for known MS risk factors, including smoking, childhood obesity, socioeconomic status, or genetics, the findings remained the same. The analysis was published in Nature…

The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3 clinical trial of its investigational treatment masitinib in people with progressive forms of multiple sclerosis (MS). The decision follows approvals in several European countries that will also host trial sites, including…

Multiple Sclerosis News Today brought consistent coverage of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS) throughout 2022. This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward…

The U.S. Food and Drug Administration has approved TG Therapeutics‘ B-cell-depleting therapy ublituximab under the brand name Briumvi for the treatment of adults with relapsing forms of multiple sclerosis (MS), the company announced. The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive…

Daily use of MS14, a natural product derived from Persian medicine, safely led to gains in physical activity and walking for people with multiple sclerosis (MS) with walking difficulties, according to data from a small placebo-controlled trial. MS14, which contains both herbal and marine ingredients, “could be used as…

About half of all individuals diagnosed with multiple sclerosis (MS) have at least one other co-occurring medical disorder, and such comorbidities add a significant economic burden for MS patients in managing their condition, according to an Italian study. These added costs result from an increase in the use of…

The European Investment Bank has entered a financial agreement with Numares Health to support further development of a fully automated platform to improve the diagnosis of chronic diseases such as multiple sclerosis (MS). The loan of up to €20 million (about $21 million) is expected to advance the…

A stem cell transplant more effectively slowed disability worsening in people with active secondary progressive multiple sclerosis (SPMS) than anti-inflammatory treatments and disease-modifying therapies (DMTs), a study has found. More transplant recipients also experienced clinical improvements that were sustained after three and five years. After 10 years,…

Severing the lower part of the vagus nerve — one of the main neurological pathways that connects the brain to the gut — led to less myelin loss in a mouse model that’s commonly used to study multiple sclerosis (MS). The findings suggest that the vagus nerve plays…

About one in five people with multiple sclerosis (MS) may be unfit to drive a vehicle due to disease-related difficulties, according to a review of published studies. Cognitive and visual difficulties were most frequently associated with impaired driving ability, both on the road and in a simulation. However, the…

Ocrevus (ocrelizumab) was equally effective in reducing disease activity after two years in people with primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS), a new study reports. The therapy also slowed disease progression in both groups, although a stronger effect was seen with RRMS patients…

Myelin, the fatty-rich material surrounding nerve fibers that’s progressively damaged in multiple sclerosis (MS), provides metabolic support to a type of nerve cell in the brain that controls the activity of other nerve cells, a study discovered. Researchers showed mitochondria, the cell’s energy producers, are specifically clustered in…

Frequency Therapeutics has established a clinical advisory board, with experts across neuroscience fields, to help guide its small molecule treatment candidate for remyelination in multiple sclerosis (MS) into clinical testing. The company is planning to initiate a first trial of the molecule, designed to boost remyelination — the…

Levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, may help predict multiple sclerosis (MS) prognosis and response to treatment with Gilenya (fingolimod), according to a review of five randomized clinical trials. Most of the evaluations in the review study were qualitative, however, meaning trial…

Higher activity of the genes SHMT1, FAM120B, and ICA1L in the brain may increase the risk of developing multiple sclerosis (MS), a new study reports that for the first time linked two of the genes to risk for the disease. The findings may help to better understand the biological…

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

Foralumab, a nasal spray therapy that Tiziana Life Sciences is developing for multiple sclerosis (MS) and other disorders, was well-tolerated in mice for more than three months, according to data from a preclinical study. Tiziana is planning to share that data in a meeting with the U.S. Food…

Researchers have created a computer program that can simulate clinical trial responses for relapsing-remitting multiple sclerosis (RRMS), which may improve clinical trial design for novel disease-modifying therapies. The tool, called MS TreatSim, was described in the study, “In silico clinical trials for relapsing-remitting multiple sclerosis…

Genetic variations in certain genes may increase the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection associated with certain treatments for multiple sclerosis (MS) and other conditions, a new study shows. The findings suggest that testing for four specific genetic variant could help to predict…

Abata Therapeutics has chosen its first treatment candidate for development: the T-cell therapy ABA-101 for certain forms of progressive multiple sclerosis (MS). The therapy is now in early studies that aim to support an investigational new drug application or IND — a formal request to U.S. regulatory authorities…

Continuous treatment with Tecfidera (dimethyl fumarate) for more than two years did not slow clinical and radiological measures of disease progression in people with primary progressive multiple sclerosis (PPMS) compared with patients who started treatment after one year. In fact, most PPMS patients remained stable with or without…

Daily exposure to 30 minutes of bright light for two weeks led to clinically significant reductions in fatigue scores among people with multiple sclerosis (MS) in a small clinical trial. “The findings from our study represent a promising non-drug therapeutic approach,” Stefan Seidel, PhD, co-author of the study…

A machine learning algorithm that incorporates genetic data alongside clinical and demographic information may be able to more accurately predict the severity of multiple sclerosis (MS), according to a new study. “Once independently validated, the machine learning algorithm could enable clinicians to provide patients with more accurate prognostic information,…

More than four years of treatment with Gilenya (fingolimod) did not cause significant swelling of the macula — a part of the retina, found in the back of the eye, and important for visual clarity — in people with relapsing-remitting multiple sclerosis (RRMS), a small study showed. While…

Noninvasive brain stimulation (NIBS) may be able to reduce fatigue, spasticity, and pain, and improve quality of life in patients with multiple sclerosis (MS), a new meta-analysis reports. The review assessed several NIBS interventions targeting different brain regions. The results suggest that these techniques can have immediate effects…

The University of British Columbia (UBC) and the VGH & UBC Hospital Foundation have received a CA$33.8 million ($25.24 million) donation to establish a multiple sclerosis (MS) research network focused on developing next-generation cell-based treatments. This private donation, by an unnamed British Columbia-based philanthropist, is thought to be the…

Patient-reported cognition difficulties — called subjective cognitive impairment (SCI) — are associated with current work status and with employment deterioration after two years in people with multiple sclerosis (MS), a new study reports. Depression and anxiety also were linked with work status among these MS patients, but such…

People with relapsing-remitting multiple sclerosis (RRMS) who are stable on rituximab treatment may receive the therapy at extended intervals without risking increased MS disease activity, according to a new study. In fact, a longer lag between infusions could potentially reduce the medication’s side effects, researchers say — noting,…